Company
Shionogi
Shionogi has 43 drugs tracked on RxWires: 2 post-market, 9 in Phase 3, 11 in Phase 2, 20 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Edaravone | Post-Market | Cerebral Infarction |
| Statin | Post-Market | Ischemic Stroke |
| Naldemedine | Phase 3 | Opioid-induced Constipation |
| Lusutrombopag | Phase 3 | Chronic Liver Disease |
| MCI-186 | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) |
| Pravafen | Phase 3 | Combined Hyperlipidemia |
| Secutrelvir | Phase 3 | SARS-CoV-2 |
| dolutegravir | Phase 3 | Infection, Human Immunodeficiency Virus |
| MT-1186 | Phase 3 | ALS |
| S-217622 | Phase 3 | SARS-CoV-2 Infection |
| Duloxetine Hydrochloride | Phase 3 | Depressive Disorder |
| Continuous infusion high-dose MCI-186 | Phase 2 | Acute Ischemic Stroke |
| JTT-302 | Phase 2 | Dyslipidemia |
| JTT-705 600 mg and simvastatin 40 mg | Phase 2 | Dyslipidemia |
| JTT-861 Capsules | Phase 2 | Chronic Heart Failure |
| S-606001 | Phase 2 | Pompe Disease |
| S-337395 | Phase 2 | Respiratory Syncytial Virus Infections |
| Redasemtide | Phase 2 | Acute Ischemic Stroke |
| S-892216 | Phase 2 | COVID-19 |
| GSK1349572 | Phase 2 | Infection, Human Immunodeficiency Virus |
| S-707106 Dose A | Phase 2 | Type 2 Diabetes Mellitus |
| S-588410 | Phase 2 | Non-small- Cell Lung Cancer |
| JTK-853 | Phase 1 | Hepatitis C Virus Infection, Response to Therapy of |
| S-648414 | Phase 1 | Healthy Volunteer |
| Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg | Phase 1 | Infection, Human Immunodeficiency Virus |
| Darunavir | Phase 1 | Healthy Volunteer |
| JTZ-951, 14C-JTZ-951 | Phase 1 | Anemia of Chronic Kidney Disease |
| Cefiderocol | Phase 1 | Pharmacokinetics |
| S-488210 | Phase 1 | Lung Cancer |
| GSK1265744 10 mg oral solution | Phase 1 | HIV Infection |
| Xeruborbactam | Phase 1 | Bacterial Infections |
| Midazolam | Phase 1 | Healthy Volunteers |
| S-892216-LAI | Phase 1 | |
| Sulthiame | Phase 1 | Renal Impairment |
| S-892216-PO | Phase 1 | Renal Impairment |
| S-888711 | Phase 1 | Healthy Volunteer |
| S309309 | Phase 1 | Obesity |
| TBI-1301 | Phase 1 | Solid Tumors |
| JTE-162 | Phase 1 | Cryopyrin-associated Periodic Syndromes (CAPS) |
| JTT-662 | Phase 1 | Diabetes Mellitus, Type 2 |
| S-3304 | Phase 1 | Solid Tumors |
| Xeruborbactam Oral Prodrug | Phase 1 | Bacterial Infections |
| NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group | Not Applicable | Autism Spectrum Disorder |
Latest
Follow Shionogi on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.